Results of Operations and Financial Condition. On August 4, 2026 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended June 30, 2026. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securi…

CAO and PAO — Sandra Calvin: Sandra Calvin is retiring, and John Torell will succeed her as CAO and PAO.

Chief Research Officer — William Rote, Ph.D.: Dr. William Rote is retiring from his position as Chief Research Officer and will be succeeded by Dr. Jula Inrig.

Entry into a Material Definitive Agreement. On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib (also known as EVER001), a covalent reversible Bruton’s tyrosine kinase (“BTK”) inhibitor, and products containing civorebrutinib (“Produ…

The filing discusses the approval of an equity incentive plan and does not involve any management changes.

Unregistered Sale of Equity Securities. To the extent that any shares of Common Stock are issued upon conversion of the Notes (the “Conversion Shares”), and at the time of conversion there is not then an effective registration statement relating to the issuance of the Conversion Shares, they will be issued in transactions anticipated to be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 3(a)(9) thereof because no commission or…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Entry into a Material Definitive Agreement. Completion of Senior Convertible Notes Offering On May 11, 2026 (the “Closing Date”), Travere Therapeutics, Inc. (the “Company”) completed its registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032 (such notes, the “Notes,” and such offering, the “Offering”) pursuant to the underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and…

below, which includes $50.0 million aggregate principal amount of Notes sold pursuant to the full exercise of the underwriters’ option to purchase additional Notes, solely to cover over-allotments. The Notes were offered and sold in a public offering registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement on Form S-3 filed with the Securities and Exchange Commission on August 1, 2024, which was effective upon filing (Registration No…

Results of Operations and Financial Condition. On May 4, 2026 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended March 31, 2026. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securiti…

Other Events. On April 13, 2026, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (“FSGS”) without nephrotic syndrome. FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS, marking its expansion beyond IgA nephropathy (“IgAN”) into a second rare kidney dis…

Results of Operations and Financial Condition. On February 19, 2026 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of S…

Other Events. On January 13, 2026, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has extended the review timeline of its supplemental New Drug Application (“sNDA”) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (“FSGS”). The new Prescription Drug User Fee Act (“PDUFA”) target action date is April 13, 2026. The extension follows the recent submission of responses requested by the FDA to further characterize the clinica…

Results of Operations and Financial Condition. On January 12, 2026, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange…

Results of Operations and Financial Condition. On October 30, 2025 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the…

Other Events. On September 10, 2025, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that following further review of the supplemental New Drug Application (“sNDA”) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (“FSGS”), an advisory committee is no longer needed. The sNDA remains under review by the FDA with a Prescription Drug User Fee Act (“PDUFA”) target action date of January 13, 2026. If a…

Results of Operations and Financial Condition. On August 6, 2025 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended June 30, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securi…

The filing discusses the approval of an equity incentive plan at the annual meeting, not a management change.

Other Events. On May 15, 2025, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted its supplemental New Drug Application (“sNDA”) for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (“FSGS”). The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) target action date of January 13, 2026, and has indicated that it is currently planning to hold an advisory committee mee…

should have been tagged instead of

Results of Operations and Financial Condition. On May 1, 2025 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended March 31, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securiti…

Results of Operations and Financial Condition. On May 1, 2025 , Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended March 31, 2025. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securiti…

Other Events. On April 29, 2025, Travere Therapeutics, Inc. (the “Company”) and CSL Vifor announced that the European Commission has approved the conversion of the conditional marketing approval (“CMA”) into a standard marketing authorization (“MA”) for FILSPARI® (sparsentan) for the treatment of adults with primary IgA nephropathy (“IgAN”) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). Standard marketing authorization is granted for all member sta…

Other Events. On March 17, 2025, Travere Therapeutics, Inc. (the “Company”) announced that it has submitted a supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (“FSGS”). The submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study. The FDA has 60 days from the receipt of the application t…

Results of Operations and Financial Condition. On February 20, 2025, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter and fiscal year ended December 31, 2024. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Se…